Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment
Key Points
The aim is to explore the role of microRNAs as biomarkers in identifying breast cancer patients who respond differently to treatment.
Analyzed microRNA profiles in breast cancer patients
Grouped patients based on chemosensitivity to fluorouracil, adriamycin, and cyclophosphamide
Identified potential predictive biomarkers and therapeutic targets
Certain microRNAs were associated with chemoresistance or chemosensitivity
MicroRNAs may provide insight into personalized treatment strategies
Findings suggest that microRNAs could be monitored for treatment responses
Abstract
Therefore, these findings suggest that miRNAs may serve as predictive biomarkers and potential therapeutic targets in the management of breast cancer.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment | Synapse
Cite This Study
Turiján-Espinoza et al. (Sun,) studied this question.